Clinical trial
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
NCT00295243 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00295243 |
|---|---|
| Title | Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies |
| Official title | A Phase I Trial of the Dual Kinase Inhibitor GW572016 in Combination With Topotecan in Patients With Advanced Solid Malignancies |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Malignancies |
| Intervention type | Drug |
| Interventions | Topotecan |
| Enrollment | 25 |
| Start date | Sep 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Feb 23, 2006 |
| Last update posted | Jan 13, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: